SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) INVESTOR ALERT: Investors With Large Losses in Sage Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Sage Therapeutics, Inc. for alleged misrepresentations regarding three of its drugs related to brain health during the specified class period from April 12, 2021, to July 23, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit involves claims that Sage Therapeutics made misrepresentations concerning zuranolone (SAGE-217/BIIB125), SAGE-718 (dalzanemdor), and SAGE-324 (BIIB124) [2]. - Investors who purchased or acquired Sage's securities during the class period are included in the lawsuit [1]. Group 2: Lead Plaintiff Information - Interested parties wishing to serve as lead plaintiff must file necessary documents by October 28, 2024 [3]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [3]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times [4].